Cardiol Therapeutics (TSE:CRDL) Trading Down 14.6% – Here’s What Happened

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price was down 14.6% during trading on Monday . The stock traded as low as C$1.24 and last traded at C$1.29. Approximately 551,069 shares changed hands during trading, an increase of 405% from the average daily volume of 109,045 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Stock Performance

The company has a debt-to-equity ratio of 1.59, a quick ratio of 6.84 and a current ratio of 2.49. The stock has a market capitalization of C$129.00 million, a P/E ratio of -3.15 and a beta of 1.31. The business has a 50-day moving average price of C$1.50 and a 200 day moving average price of C$1.64.

Cardiol Therapeutics (TSE:CRDL) last issued its quarterly earnings results on Thursday, November 13th. The company reported C($0.12) earnings per share for the quarter. As a group, sell-side analysts forecast that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.